Urgent.News

What's breaking now, across thousands of outlets.

Business

Career: Changing jobs in uncertain times: Should I take the risk?

Out of the nest you've made, into the unknown: Despite the uncertain economic situation, this can be the perfect career move right now. Who should make a change now - and who shouldn't.

Translated from German Read in German

Career: Changing jobs in uncertain times: Should I take the risk?

In uncertain economic times, many employees are hesitant to switch employers due to a need for security. However, experts like Georg Scheiber from von Rundstedt in Nürnberg advise actively exploring career goals and options. Employees should assess their current standing and future prospects within their company and consider changing employers if their job is at risk. A strategic approach to changing employers can be beneficial, especially in times of economic uncertainty.

Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.

Read the original at handelsblatt.com →

More in Business

Creators are now classified as small businesses, but what does that actually mean?

The Small Business Administration has officially welcomed creators under its umbrella; let's unpack what that means for brands, creators, and the economy at large.

  • U.S. SBA releases classification guidance for content creators on Oct 15
  • Creators now fall under Motion Picture and Video industries category
  • SBA support eligibility clarified for creator-led businesses

GC Cell Presents GCC2005 Phase 1a Progress

GC Cell has shared clinical progress on 'GCC2005,' an allogeneic CAR-NK cell therapy it is developing for the treatment of refractory T-cell lymphoma, on the international stage.The company said it…

  • GC Cell presented Phase 1a interim results for GCC2005 at Eastern Breeze Symposium in October 2026
  • Symposium marked 20th anniversary of Lymphoma Working Party of Korean Society of Hematology
  • GC Cell conducting domestic Phase 1b trial to expedite commercialization of GCC2005

More from Wednesday 28 October →